The Antiviral Drugs Market was valued at approximately USD 63 billion in 2023 and is expected to grow at a substantial CAGR of around 5% during the forecast period (2024-2032)

Rising Chronic Diseases to Boost Global Antiviral Drugs Market Growth

The global antiviral drugs market is poised for steady expansion, driven primarily by the rising incidence of chronic viral infections and the growing need for advanced therapeutic solutions. Antiviral medicines are used to manage viral diseases such as HIV, hepatitis, influenza, and herpes. As viral outbreaks continue to evolve across the world, the demand for effective antiviral treatments and preventive therapies continues to rise.

According to World Health Organization (WHO) estimates, approximately 1.5 million new hepatitis B infections are recorded annually, while nearly 296 million people were living with chronic hepatitis B in 2019. A similar upward trend is being seen in other viral conditions such as influenza, herpes simplex virus (HSV), and HIV—collectively contributing to sustained growth in the antiviral drug landscape. Increased R&D funding, advancements in drug development, and broader access to healthcare also play crucial roles in shaping this market.

Market Outlook and Growth Drivers

UnivDatos Market Insights (UMI) projects the antiviral drugs market to grow at a CAGR of around 3.4% between 2021 and 2027. The expansion is encouraged by government support for drug research, the emergence of new biotechnology firms, and the ongoing development of innovative antiviral therapies.

Segmentation Overview

By Drug Class:

The market is categorized into reverse transcriptase inhibitors, protease inhibitors, and other antiviral classes. Reverse transcriptase inhibitors held the largest share in 2020, generating revenues exceeding USD 11 billion by 2021. These drugs form a major component of HIV and hepatitis treatment regimens. With high rates of sexually transmitted infections and increasing adult population demographics, demand for these medications is anticipated to remain strong. WHO reports that nearly 491 million people aged 15–49 were living with HSV-2 infections as of 2016, underscoring the need for expanded therapeutic options.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/antiviral-drugs-market?popup=report-enquiry

By Distribution Channel:

Antiviral drugs are distributed through hospitals and clinics, retail and drug stores, and online pharmacies. Online pharmacies are expected to grow at the fastest rate, supported by improved internet accessibility, rising digital health adoption, and evolving regulatory frameworks. In North America, online pharmacies typically operate within prescription-based models, while regions like Europe and Asia-Pacific are seeing more nonprescription-focused digital platforms.

Regional Insights

Among the major global regions, Asia-Pacific is projected to witness the highest growth rate. The region’s expanding elderly population, strong pharmaceutical manufacturing base, and increasing investments in healthcare infrastructure are key contributors. Countries like India, China, and South Korea remain central hubs for drug development, making Asia-Pacific a focal point for antiviral research and commercialization.

Click here to view the Report Description & TOC: https://univdatos.com/reports/antiviral-drugs-market

Competitive Landscape

Leading players in the antiviral drugs market include:

Gilead Sciences

AbbVie Inc.

Merck & Co.

GlaxoSmithKline plc

Aurobindo Pharma

Johnson & Johnson

Sun Pharmaceutical Industries

Cipla

Mylan N.V.

Bristol-Myers Squibb

These companies are actively investing in R&D, expanding product portfolios, and forming strategic collaborations. Notable developments include Aurobindo Pharma’s 2022 launch of Molnaflu (molnupiravir) for COVID-19 treatment in India, and Pfizer’s multi-year agreement with Gilead to manufacture remdesivir for global COVID-19 response efforts.

Market Scope and Opportunities

The antiviral drugs market report from UnivDatos Market Insights offers detailed insights covering market drivers, emerging opportunities, regulatory considerations, and competitive benchmarking. The study also highlights evolving patient behavior, digital healthcare adoption, and the shift toward combination therapies.

Market Segmentation Summary

Drug Class: Reverse transcriptase inhibitors, protease inhibitors, others

Application: HIV, hepatitis, herpes, influenza, and more

Distribution Channel: Hospitals & clinics, retail pharmacies, online pharmacies

Region: North America, Europe, Asia-Pacific, Rest of World

Contact Us:

UnivDatos

Email: contact@univdatos.com 

Contact no: +1 978 7330253

Website: www.univdatos.com

Linked In: https://www.linkedin.com/company/univ-datos/